Osterweis Capital Management, an investment management firm, released its Q1 2026 investor update for its “Osterweis Opportunity Fund”. A copy of the letter can be downloaded here. The fund returned -3.78% in the quarter compared to -2.81% for the Russell 2000 Growth Index. The fund’s long-term returns stay positive, but recent geopolitical shocks and AI disruption concerns pressured quarterly results. Security selection boosted performance, whereas sector allocation was a significant drag. Although the firm’s investment approach remains consistent, it continues to seek innovative companies in growing markets. In addition, you can check the Fund’s top 5 holdings for its best picks for 2026.
In its first-quarter 2026 investor letter, Osterweis Opportunity Fund highlighted Repligen Corporation (NASDAQ:RGEN). Repligen Corporation (NASDAQ:RGEN) is a life science company that develops and distributes bioprocessing technologies and systems. On June 18, 2026, Repligen Corporation (NASDAQ:RGEN) closed at $132.02 per share. One-month return of Repligen Corporation (NASDAQ:RGEN) was 14.74%, and its shares gained 11.08% over the past 52 weeks. Repligen Corporation (NASDAQ:RGEN) has a market capitalization of $7.45 billion.
Osterweis Opportunity Fund stated the following regarding Repligen Corporation (NASDAQ:RGEN) in its Q1 2026 investor letter:
“Repligen Corporation (NASDAQ:RGEN), a provider of bioprocessing products, detracted most from our relative returns, as enthusiasm for life-sciences tools generally softened during the period. The concerns were driven by a slowdown in purchasing by the National Institutes of Health (NIH), which affected the entire sector. Importantly, Repligen has no exposure to NIH and offered bullish Q1 guidance, so we remain positive about the business. Also, we expect sentiment surrounding life-sciences tools to improve in the second quarter, which should lead to a reversal of the negative momentum.”
Repligen Corporation (NASDAQ:RGEN) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 40 hedge fund portfolios held Repligen Corporation (NASDAQ:RGEN) at the end of the first quarter, up from 43 in the previous quarter. In Q1 2026, Repligen Corporation (NASDAQ:RGEN) reported revenue of $194 million, marking an increase of 15% year over year. While we acknowledge the risk and potential of Repligen Corporation (NASDAQ:RGEN) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than REPLIGEN CORPORATION (NASDAQ:RGEN) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Repligen Corporation (NASDAQ:RGEN) and shared Billionaire Lee Ainslie’s stocks with huge upside potential. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
